January 14, 2021 – Eyenuk today announced its partnership with Alta Tecnología Médica S.A. (ATM), a leading provider of advanced medical technologies in Chile for the distribution of EyeArt® artificial intelligence (AI) system for autonomous diabetic retinopathy detection. Chile has the second highest incidence of diabetes in South America with nearly 2 million people with diabetes.
In operation for 26 years, ATM’s team of over 50 experienced healthcare professionals are dedicated to offering world-class service and continuously introducing new technologies to improve healthcare delivery throughout Chile. ATM’s current business portfolio covers market leading products in multiple clinical specialties, including ophthalmology, vascular, interventional, urology and dermatology.
“We are excited to partner with Eyenuk to bring the EyeArt system to the Chilean market,” said Guillermo Godoy, ATM President & CEO. “After extensive evaluation of AI technologies around the world, we determined that the EyeArt system is the best AI technology for diabetic retinopathy detection, not only for being FDA approved but also the most validated system we could find. We believe that the EyeArt system can save vision for many diabetes patients in Chile, and this is part of our mission.”
The launch into Chile represents an important milestone in Eyenuk’s expansion into Latin America, where the EyeArt system is currently available for marketing in multiple countries. Outside of Latin America, the EyeArt system is in regular clinical use throughout North America, Europe, Africa and India.